Capricor Therapeutics Makes Strides in Duchenne Muscular Dystrophy Treatment: FDA Meetings and Positive Study Results Propel BLA Pathway
Capricor Therapeutics, a biotechnology company specializing in cell and exosome-based therapeutics for rare diseases, has recently announced positive developments in their CAP-1002 program for Duchenne Muscular Dystrophy (DMD). Following a successful Type-B meeting with the FDA, the company aims to expedite the Biologics License Application (BLA) pathway for CAP-1002. Deramiocel has been selected as the proposed International Nonproprietary Name (INN) for the treatment, and the company is set to present updates on their exosome platform at the American Society of Gene and Cell Therapy’s 27th Annual Meeting.
Additionally, Capricor Therapeutics presented positive 24-month results from the HOPE-2 Open Label Extension Study of CAP-1002 at the Muscular Dystrophy Association’s Clinical & Scientific Conference. These results highlight the potential of CAP-1002 in treating DMD and showcase the company’s commitment to advancing innovative therapies for rare diseases.
Overall, these developments signal a promising future for Capricor Therapeutics and reinforce their position as a leader in the field of Duchenne Muscular Dystrophy treatment.
Comments